Consensus Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
9.73 ^USD	-2.01%		+3.07%	-3.28%

May. 15	Transcript : Vir Biotechnology, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 04:20 PM
May. 02	Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024

Evolution of the average Target Price on Vir Biotechnology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a387bc34f73678057aa1e3cf83fcb2.PftM9ul0rbXKFc9xpai4K2v26XiS2yejmWRdq-oN45I.RagjnatEwtGaRpw6756LE0bBjRfQt1H3-C0z_6lMgepiyTTBvjvJh6R5ig~476d9cf8753de7bd7424f0f8e5514120

Analyst Recommendations on Vir Biotechnology, Inc.

HC Wainwright Adjusts Vir Biotechnology Price Target to $110 From $85, Maintains Buy Rating	Feb. 14	MT
JPMorgan Downgrades Vir Biotechnology to Neutral From Overweight, Cuts Price Target to $9 From $23	Jan. 29	MT
BofA Securities Downgrades Vir Biotechnology to Neutral From Buy, Cuts Price Target to $14 From $23 After Shares Underperformance	23-09-08	MT
BofA Securities Downgrades Vir Biotechnology to Neutral From Buy, Adjusts Price Target to $14 From $23	23-09-08	MT
HC Wainwright Adjusts Price Target on Vir Biotechnology to $95 From $100, Keeps Buy Rating	23-08-07	MT
JPMorgan Cuts Vir Biotechnology's Price Target to $24 From $34, Maintains Overweight Rating	23-07-21	MT
Goldman Sachs Adjusts Vir Biotechnology's Price Target to $28 From $51, Keeps Buy Rating	23-07-21	MT
Barclays Adjusts Price Target on Vir Biotechnology to $41 From $59, Maintains Overweight Rating	23-07-21	MT
Morgan Stanley Cuts Vir Biotechnology's Price Target to $15 From $27, Maintains Equalweight Rating	23-07-20	MT
Needham Cuts Vir Biotechnology's Price Target to $22 From $32, Maintains Buy Rating	23-07-20	MT
Morgan Stanley Adjusts Price Target on Vir Biotechnology to $27 From $25, Maintains Equal-Weight Rating	23-04-04	MT
JPMorgan Upgrades Vir Biotechnology to Overweight From Neutral, Adjusts Price Target to $34 From $35	23-03-06	MT
HC Wainwright Adjusts Price Target on Vir Biotechnology to $100 From $125, Keeps Buy Rating	23-03-06	MT
Goldman Sachs Upgrades Vir Biotechnology to Buy From Neutral, Adjusts Price Target to $53 From $41	23-02-21	MT
Morgan Stanley Upgrades Vir Biotechnology to Equal Weight From Underweight, Adjusts Price Target to $30 From $18	23-01-27	MT
SVB Securities Adjusts Vir Biotechnology's Price Target to $43 From $45, Maintains Outperform Rating	23-01-27	MT
Needham Adjusts Price Target on Vir Biotechnology to $32 From $35, Maintains Buy Rating	22-11-04	MT
SVB Securities Starts Vir Biotechnology at Outperform With $40 Price Target	22-09-14	MT
Morgan Stanley Initiates Vir Biotechnology at Underweight With $15 Price Target	22-09-09	MT
HC Wainwright Adjusts Vir Biotechnology Price Target to $125 From $200, Maintains Buy Rating	22-05-12	MT
HC Wainwright Adjusts Vir Biotechnology's Price Target to $200 From $300, Reiterates Buy Rating	22-03-30	MT
Needham Adjusts Vir Biotechnology's Price Target to $45 from $80, Keeps Buy Rating	22-03-28	MT
Baird Upgrades Vir Biotechnology to Neutral From Underperform, Adjusts Price Target to $28 From $36	22-03-03	MT
HC Wainwright Adjusts Vir Biotechnology's Price Target to $300 from $200, Keeps Buy Rating	21-12-21	MT
Baird Downgrades Vir Biotechnology to Underperform From Neutral; Price Target is $36	21-12-21	MT